Continuing Medical Education European Persepctive on AIDS 2018

AIDS 2018 EU web banner




About the Program

Program Overview

The ARV Therapies and Therapeutic Strategies program is a comprehensive, independent review of the 22nd International AIDS Conference (AIDS 2018). This program consists of four components: (1) CME Internet Symposium: AIDS 2018 Expert Review: a 1.5 hour Internet symposium that features an overview and discussion of key presentations and posters, selected by the expert faculty discussants; (2) European Perspective on AIDS 2018: a 1 hour panel discussion featuring Europe-based expert faculty reviewing and discussing key presentations with a focus on clinical management and treatment in the EU; (3) Rapid-Fire Review of AIDS 2018: a podcast that provides a brief, audio summary of the most essential data presented at the conference; and (4) From Conference to Clinic: Reviewing and Applying Data From AIDS 2018: case-based dinner meetings during which the key data are reviewed, discussed and applied to patient care.

The European Perspective on AIDS 2018 will provide a case-based, European focused review and discussion of key presentations on antiretroviral therapy presented at EACS 2017. The review and discussion will focus on HIV therapeutic options and developments, including: current treatment and management strategies, algorithms and recommendations, therapies in development, epidemiology, and diagnosis and clinical management of specific patient populations. This activity will enable EU-based health care providers caring for HIV-infected patients to become aware of and understand the data presented at this important conference and appropriately utilize those data to improve patient care in the EU. All online components of the program can be accessed at

This program is produced by the Postgraduate Institute for Medicine and ViralEd, Inc. It is not a session created by or presented at AIDS 2018 and it is not sanctioned by the organizers of AIDS 2018.

Back to Top

Target Audience

This activity has been designed to meet the educational needs of physicians, physician assistants, advanced practice nurses and other health care professionals involved in the care of patients with HIV infection.

Back to Top

Learning Objectives

After completing this activity, participants should be better able to:

  • Use data reported at AIDS 2018 for counseling, testing and antiretroviral treatment to prevent HIV infection in the EU
  • Apply the findings from key studies on HIV/AIDS diagnosis, management, and treatment presented at AIDS 2018
  • Employ strategies based on studies and data presented at AIDS 2018 for helping HIV-positive patients in the EU link to and stay in appropriate and effective HIV care
  • Describe data and studies regarding the screening, evaluation, management, and treatment of HCV in HIV/HCV co-infected patients presented at AIDS 2018 and use that information to educate, diagnose, manage, and treat HIV/HCV co-infected patients and those HIV patients at risk for HCV

Release Date: August 3, 2018

Expiration Date: August 3, 2019

Estimated time to complete the program:  1 hour, 15 minutes

Back to Top


José Arribas, MD
Senior Attending Physician, HIV Unit
Hospital de La Paz
Madrid, Spain

Marta Boffito, MD, PhD
St. Stephen’s AIDS Trust and Imperial College
Chelsea and Westminster Hospital
London, United Kingdom

Franco Maggiolo, MD
Head, Infectious Diseases Department
Papa Giovanni XXIII Hospital
Bergamo, Italy

Graeme Moyle, MD, MB, BS
Associate Director of HIV Research
Chelsea & Westminster Hospital
London, United Kingdom 

Jürgen Rockstroh, MD
Professor of Medicine
Department of Medicine
University Hospital
Bonn, Germany

Back to Top

European Continuous Medical Education Credit

AMA PRA Category 1 Credits™ claimed by physicians attending live events certified and organized in the United States for AMA PRA Category 1 Credits™ can be claimed through the agreement on mutual recognition of credits between UEMS and AMA, considered as being equal to the European Continuous Medical Education Credits (ECMEC®) granted by the UEMS. One AMA PRA Category 1 Credit™ is equivalent to one (1) hour of European EACCME Credit (ECMEC®), therefore up to 1.0 ECMEC® Credits are available.

Back to Top

Joint Accreditation Statement


In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and ViralEd, Inc. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Complete Program

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


For Individual Modules

The Postgraduate Institute for Medicine designates each enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Back to Top

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Jose Arribas, MD

  • Consulting Fees: Merck, Gilead, ViiV, Gilead, Janssen

Marta Boffito, MD

  • Consulting Fees: Gilead, BMS, ViiV
  • Fees for Non-CME/CE Services Received Directly from a Commercial Interest or thier agents (eg. speakers' bureaus): Gilead, Janssen, ViiV, BMS
  • Contracted Research: Gilead, Janssen, ViiV, BMS

Graeme Moyle, MD

  • Consulting Fees: Gilead, Merck, Janssen
  • Contracted Research: ViiV, Gilead, Amgen (to institution)

Juergen Rockstroh, MD

  • Consulting Fees: Abbott, Abbivax, Gilead, Hexal, Janssen, Merck, ViiV
  • Contracted Research: Gilead, Merck

Franco Maggiolo, MD

  • Consulting Fees: BI, BMS, Gilead, GSK, Tibotec
  • Fees for Non-CME/CE Services Received Directly from a Commercial Interest or thier agents (eg. speakers' bureaus): BMS, Gilead, GSK, Merck Sharp and Dome
  • Contracted Research: BI, BMS, GSK, Janssen-Cilag and Roche

Renslow Sherer, MD

  • Consulting Fees: Gilead
The PIM planners and managers, Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CHCP; Judi Smelker-Mitchek, RN, BSN and Jan Shultz, RN, MSN, CHCP have nothing to disclose.
Back to Top

Method of Participation and Request for Credit

There are no fees for participating and receiving CME/CE credit for this activity. During the period, August 3, 2018 through August 3, 2019, participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, please complete the evaluation on On the navigation menu, click on "Find Post-test/Evaluation by Course" and search by course ID 13398. Upon registering and successfully completing the activity evaluation, your certificate will be made available immediately.

Back to Top

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Back to Top


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Back to Top

Computer System Requirements

This program requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome). Certain educational activities may require additional software to view multimedia, presentation, or printable version of their content.  These activities will be marked as such and will provide links to the required software.  That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player and Real Networks Real One Player.  

Back to Top


    PIM_small    VE logo 300px



This activity is supported by an independent educational grant from Gilead Sciences Medical Affairs.

This coverage is not sanctioned by the conference organizers and is not an official part of the conference proceedings.


Back to Top



Prepare to print

Share this page:

Get link code to this page     

Back to Top